Sanofi (SNYNF) Other Non-Current Liabilities (2009 - 2025)
Sanofi's (SNYNF) quarterly Other Non-Current Liabilities came in at $7.8 billion in Q4 2025, down 9.81% year-on-year from $8.7 billion in Q4 2024, and down 3.13% quarter-over-quarter from $8.1 billion in Q2 2025.
Sanofi (SNYNF) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends
Sanofi has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $7.8 billion for Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $7.8 billion, down 9.81% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.8 billion (down 9.81% YoY), and the FY2025 annual result was $7.8 billion, down 9.81% from the prior year.
- Other Non-Current Liabilities came in at $7.8 billion for Q4 2025 at Sanofi, down from $8.1 billion in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $8.9 billion in Q2 2024 to a low of $1.3 billion in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $7.9 billion (2025), against an average of $6.7 billion.
- Across the five-year window, Other Non-Current Liabilities decreased 28.44% in 2021 and jumped 550.2% in 2023, its largest moves.
- Sanofi's Other Non-Current Liabilities stood at $1.3 billion in 2021, then slipped by 1.64% to $1.3 billion in 2022, then surged by 550.2% to $8.2 billion in 2023, then grew by 5.77% to $8.7 billion in 2024, then decreased by 9.81% to $7.8 billion in 2025.
- The last three Other Non-Current Liabilities figures came in at $7.8 billion (Q4 2025), $8.1 billion (Q2 2025), and $8.7 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.80 Bn |
| Jun 30, 2025 | 8.06 Bn |
| Dec 31, 2024 | 8.65 Bn |
| Jun 30, 2024 | 8.85 Bn |
| Dec 31, 2023 | 8.18 Bn |
| Jun 30, 2023 | 7.72 Bn |
| Dec 31, 2022 | 1.26 Bn |
| Jun 30, 2022 | 6.60 Bn |
| Dec 31, 2021 | 1.28 Bn |
| Jun 30, 2021 | 8.46 Bn |
| Dec 31, 2020 | 1.79 Bn |
| Jun 30, 2020 | 10.78 Bn |
| Dec 31, 2019 | 1.54 Bn |
| Jun 30, 2019 | 10.22 Bn |
| Dec 31, 2018 | 8.22 Bn |
| Sep 30, 2018 | 31.40 Mn |
| Jun 30, 2018 | 35.80 Mn |
| Mar 31, 2018 | 10.70 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Jun 30, 2017 | 9.25 Bn |